CD44 cell surface marker, SP cells and ALDHBr cells have been reported as stem cell markers for gynecological malignancies using cell lines OVCAR3, HEC-1 and other lines and primacy samples [11]–[14], and CSC/CIC research may improve the outcome of advanced ovarian cancer patients. This evidence concerns the gene CD44 and ovarian carcinoma.